Peptides for Anti-Aging
Reviewed by Marcus Hopkin, PhD
Director of Research and Development, Volta Peptides
Written by Volta Peptides Editorial Team · Reviewed September 16, 2026
Comprehensive guide to 15 peptides researched for anti-aging, ranked by evidence strength from FDA-approved to early preclinical. Each compound is evaluated on mechanism, clinical status, and safety profile.
Overview
15 research peptides are currently studied for anti-aging. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
SS-31 — FDA Approved
Evidence Rating: A
Category: Metabolic / Mitochondrial
SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane, binding to cardiolipin and stabilizing cristae structure. It is being developed by Stealth BioTherapeutics for mitochondrial diseases, heart failure, and age-related mitochondrial dysfunction. It has undergone multiple Phase I–III clinical trials, including the TAZPOWER trial for Barth syndrome.
Key claims: Improves mitochondrial function; Reduces cardiac dysfunction.
Sermorelin — Phase I–II Clinical Trials
Evidence Rating: C
Category: Growth Hormone Secretagogue
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It was previously FDA-approved as Geref for the diagnosis and treatment of growth hormone deficiency in children, though the product was voluntarily discontinued for commercial reasons — the FDA confirmed in 2013 it was not withdrawn for safety reasons. It preserves the body's natural GH feedback loop via somatostatin, making it safer than exogenous HGH. The 1997 JCEM trial remains the most substantial evidence for its effects in adults, demonstrating improvements in IGF-1, body composition, and well-being over 5 months.
Key claims: Stimulates endogenous growth hormone release; Improves body composition in adults.
MK-677 — Phase I–II Clinical Trials
Evidence Rating: C
Category: Growth Hormone Secretagogue
MK-677 (Ibutamoren) is a potent, long-acting, orally-active, non-peptide ghrelin receptor (GHS-R1a) agonist that stimulates growth hormone release without injections. Unlike injectable GH peptides such as GHRP-6 or Ipamorelin, MK-677 can be taken orally and maintains elevated GH and IGF-1 levels for up to 24 hours. It has been studied in several human clinical trials for GH deficiency, muscle wasting, bone density, and sleep quality, but is not FDA-approved for any indication.
Key claims: Increases growth hormone and IGF-1 levels; Improves sleep quality.
Hexarelin — Phase I–II Clinical Trials
Evidence Rating: C
Category: Growth Hormone Secretagogue
Hexarelin is a synthetic hexapeptide growth hormone secretagogue that binds to the ghrelin receptor (GHS-R1a). It is considered one of the most potent GHRPs available, stimulating greater GH release than GHRH alone. However, it causes relatively rapid receptor desensitization compared to milder GHRPs like ipamorelin, limiting cycle duration to 4-8 weeks. It also has notable cardioprotective properties independent of GH release.
Key claims: Potent GH release; Cardioprotective effects.
GHK (Glycyl-Histidyl-Lysine) — Early Human / Mixed Evidence
Evidence Rating: C
Category: Regenerative / Research
GHK is a naturally occurring tripeptide first isolated from human plasma. It declines significantly with age. Even without copper complexation, GHK demonstrates gene-regulatory activity affecting over 4,000 genes related to tissue repair, immune function, and anti-inflammatory responses.
Key claims: Broad gene expression modulation; Wound healing acceleration.
Ipamorelin — Preclinical
Evidence Rating: D
Category: Growth Hormone Secretagogue
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol, prolactin, or appetite. It is widely regarded as the mildest GHS, making it popular in anti-aging, body composition, and recovery contexts. However, research on ipamorelin is limited, and it is not FDA-approved for any indication.
Key claims: Increases growth hormone levels; Improves body composition.
CJC-1295 — Preclinical
Evidence Rating: D
Category: Growth Hormone Secretagogue
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition.
MOTS-c — Preclinical
Evidence Rating: D
Category: Metabolic / Mitochondrial
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at USC, it acts as a metabolic regulator primarily through AMPK activation. In mouse models, MOTS-c prevents diet-induced obesity and insulin resistance, enhances exercise capacity (old mice ran 2x longer on treadmill tests), and reduces age-related metabolic decline. A modified analog (CB4211) showed good tolerability in a Phase 1 human trial. No clinical trials of native MOTS-c in humans have been completed.
Key claims: Improves insulin sensitivity and glucose metabolism; Exercise mimetic effects.
Epithalon — Preclinical
Evidence Rating: D
Category: Anti-Aging / Telomere
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly, MW ~390 g/mol) developed by Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary mechanism involves telomerase activation to maintain telomere length. Secondary mechanisms include melatonin enhancement via pineal gland restoration, hormonal balance improvement, and antioxidant defense. Extensive Russian research spanning 20+ years of clinical use reports safety and efficacy, but Western clinical trials remain minimal. Animal studies show lifespan extension of up to 13.3% in the last 10% of survivors (p<0.05).
Key claims: Activates telomerase and extends telomeres; Extends lifespan in animal models.
FOXO4-DRI — Preclinical
Evidence Rating: D
Category: Senolytic / Anti-Aging
FOXO4-DRI is a D-retro-inverso peptide designed to selectively eliminate senescent cells — aged, dysfunctional "zombie cells" that accumulate in tissues and drive chronic inflammation, tissue dysfunction, and age-related disease. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive, causing them to undergo apoptosis while leaving healthy cells unaffected. It is one of the first peptide-based senolytics and has generated significant interest in the longevity research community.
Key claims: Selectively eliminates senescent cells; Reverses age-related vascular decline.
Humanin — Preclinical
Evidence Rating: D
Category: Metabolic / Mitochondrial
Humanin is a 21-24 amino acid mitochondria-derived peptide (MDP) encoded by the MT-RNR2 gene in mitochondrial DNA. It was originally discovered in 2001 for its ability to protect neurons from Alzheimer's disease-related toxicity. Since then, it has been found to have broad cytoprotective, anti-inflammatory, anti-apoptotic, and metabolic effects. Circulating humanin levels decline with age and correlate with longevity in centenarian studies.
Key claims: Neuroprotection against Alzheimer's toxicity; Cardioprotection.
N-Acetyl Epithalon Amidate — Limited Evidence
Evidence Rating: D
Category: Anti-Aging / Research
N-Acetyl Epithalon Amidate is a chemically modified version of epithalon (Ala-Glu-Asp-Gly) with N-terminal acetylation and C-terminal amidation. These modifications protect against enzymatic degradation, potentially improving half-life and bioavailability.
Key claims: Enhanced stability vs standard epithalon; Terminal modifications block exopeptidase degradation.
Shop Research Peptides
Sermorelin 5mg
CJC-1295 DAC 5mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
Tesamorelin vs Ipamorelin: Human Evidence, Doses, Safety
Tesamorelin holds FDA approval for HIV-associated lipodystrophy; ipamorelin has none. This page maps the published human dosing data for each and marks the gaps.
Peptide Tools
Key research references
- Best Peptides for Metabolic Health | Research Guide
- Best Peptides for Weight Management | Research Guide
- Best Peptides for Body Composition | Research Guide
- Best Peptides for Reproductive Health | Research Guide
- Best Peptides for Anti-Aging & Longevity | Research Guide
- Best Peptides for Weight Loss | Research Guide
- Best Peptides for Cognitive Enhancement | Research Guide
- Retatrutide Dosing Guide | Protocols & Reconstitution
- Wound Healing Peptides | Research Compounds
- Muscle Growth Peptides | Research Compounds
- Immune Modulation Peptides | Research Compounds
Browse the research catalogue
Buying and verification
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
SubscribeFrequently Asked Questions
Related Research
About the reviewer
Director of Research and Development, Volta Peptides
Marcus Hopkin, PhD, is Director of Research and Development at Volta Peptides. He has more than 12 years of analytical chemistry experience, including direct laboratory work in peptide synthesis, characterization, purity testing and stability assessment. His doctoral research at the University of Michigan examined novel peptide structures in the human proteome and their potential significance for therapeutic-peptide research. Before joining Volta Peptides he held research and development roles at Amgen and Eli Lilly and Company, and served as a lecturer at the University of Michigan.
Marcus reviewed this article for scientific and analytical accuracy on September 16, 2026. He did not write it. Technical review is internal review and is not peer review, independent third-party review or medical review.
Disclosure. Marcus Hopkin is an employee of Volta Peptides and serves as its Director of Research and Development. Volta Peptides sells research compounds related to subjects discussed in the content he writes and reviews. His reviews are internal scientific and technical review and must not be described as independent third-party review, peer review or medical review.